公开(公告)号：WO2006019660A3

公开(公告)日：2006-05-11

申请号：PCT/US2005024447

申请日：2005-07-08

Applicant: ABBOTT LAB ,  BUCKLEY MICHAEL J ,  JI JIANGUO ,  ZHANG GEOFF G ,  HENRY RODGER F ,  WANG WEILI W ,  WAYNE GREG S ,  LI WENKE ,  TOWNE TIMOTHY B ,  WITTENBERGER STEVEN J ,  HANNICK STEVEN M ,  KOTECKI BRIAN J ,  MARCI BRYAN S ,  ROBBINS TIMOTHY A

Inventor： BUCKLEY MICHAEL J ,  JI JIANGUO ,  ZHANG GEOFF G ,  HENRY RODGER F ,  WANG WEILI W ,  WAYNE GREG S ,  LI WENKE ,  TOWNE TIMOTHY B ,  WITTENBERGER STEVEN J ,  HANNICK STEVEN M ,  KOTECKI BRIAN J ,  MARCI BRYAN S ,  ROBBINS TIMOTHY A

IPC: C07D487/04 ,  A61K31/4439

CPC classification number: C07D487/04

Abstract: The present invention discloses (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane, salts thereof, and its use to treat pain and other disorders associated with the nicotinic acetylcholine receptor.

Abstract translation: 本发明公开了（1S，5S）-3-（5,6-二氯-3-吡啶基）-3,6-二氮杂双环[3.2.0]庚烷及其盐，其用于治疗与 烟碱乙酰胆碱受体。

公开(公告)号：WO2006019660A2

公开(公告)日：2006-02-23

申请号：PCT/US2005/024447

申请日：2005-07-08

Applicant: ABBOTT LABORATORIES ,  BUCKLEY, Michael, J. ,  JI, Jianguo ,  ZHANG, Geoff, G. ,  HENRY, Rodger, F. ,  WANG, Weili, W. ,  WAYNE, Greg, S. ,  LI, Wenke ,  TOWNE, Timothy, B. ,  WITTENBERGER, Steven, J. ,  HANNICK, Steven, M. ,  KOTECKI, Brian, J. ,  MARCI, Bryan, S. ,  ROBBINS, Timothy, A.

Inventor： BUCKLEY, Michael, J. ,  JI, Jianguo ,  ZHANG, Geoff, G. ,  HENRY, Rodger, F. ,  WANG, Weili, W. ,  WAYNE, Greg, S. ,  LI, Wenke ,  TOWNE, Timothy, B. ,  WITTENBERGER, Steven, J. ,  HANNICK, Steven, M. ,  KOTECKI, Brian, J. ,  MARCI, Bryan, S. ,  ROBBINS, Timothy, A.

IPC: A61K31/4439 ,  C07D487/04

CPC classification number: C07D487/04

Abstract: The present invention discloses (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane, salts thereof, and its use to treat pain and other disorders associated with the nicotinic acetylcholine receptor.

Abstract translation: 本发明公开了（1S，5S）-3-（5,6-二氯-3-吡啶基）-3,6-二氮杂双环[3.2.0]庚烷及其盐，及其用途 以治疗与烟碱乙酰胆碱受体相关的疼痛和其他疾病。

公开(公告)号：WO2005012273A2

公开(公告)日：2005-02-10

申请号：PCT/US2004/024758

申请日：2004-07-30

Applicant: ABBOTT LABORATORIES ,  ROBBINS, Timothy, A. ,  ZHU, Helen ,  SHAO, Jun

Inventor： ROBBINS, Timothy, A. ,  ZHU, Helen ,  SHAO, Jun

IPC: C07D277/56

CPC classification number: C07D277/56

Abstract: This invention is directed to processes for making substituted thiazoles. The substituted thiazole, ethyl 2-(4-hydroxyphenyl)-4-methyl-1,3-thiazole-5-carboxylate, also known as TEI-6720, is useful for treatment of gout and hyperuricemia. This compound belongs to a class of substituted thiazoles that inhibit xanthine oxidase and thus block uric acid production.

Abstract translation: 本发明涉及制备取代噻唑的方法。 取代的噻唑，2-（4-羟基苯基）-4-甲基-1,3-噻唑-5-羧酸乙酯，也称为TEI-6720，可用于治疗痛风和高尿酸血症。 该化合物属于一类抑制黄嘌呤氧化酶并因此阻断尿酸生产的取代噻唑类。

公开(公告)号：WO2005012273A3

公开(公告)日：2005-05-12

申请号：PCT/US2004024758

申请日：2004-07-30

Applicant: ABBOTT LAB ,  ROBBINS TIMOTHY A ,  ZHU HELEN ,  SHAO JUN

Inventor： ROBBINS TIMOTHY A ,  ZHU HELEN ,  SHAO JUN

IPC: C07D277/56

CPC classification number: C07D277/56

Abstract: This invention is directed to processes for making substituted thiazoles. The substituted thiazole, ethyl 2-(4-hydroxyphenyl)-4-methyl-1,3-thiazole-5-carboxylate, also known as TEI-6720, is useful for treatment of gout and hyperuricemia. This compound belongs to a class of substituted thiazoles that inhibit xanthine oxidase and thus block uric acid production.

Abstract translation: 本发明涉及制备取代噻唑的方法。 取代的噻唑，2-（4-羟基苯基）-4-甲基-1,3-噻唑-5-羧酸乙酯，也称为TEI-6720，可用于治疗痛风和高尿酸血症。 该化合物属于一类可抑制黄嘌呤氧化酶并因此阻断尿酸生产的取代噻唑类。